SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Core Insights - SAB Biotherapeutics, Inc. is set to present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) from September 15 to 19, 2025, showcasing its innovative immunotherapy platform targeting autoimmune type 1 diabetes (T1D) [1][4] Company Overview - SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs) to treat and prevent immune and autoimmune disorders, specifically targeting autoimmune T1D with its lead asset, SAB-142 [8] - The company utilizes advanced genetic engineering and antibody science to create Transchromosomic (Tc) Bovine™, which allows for the production of a diverse range of specifically targeted, high-potency human IgGs without the need for human donors or convalescent plasma [8] EASD Presentations - The company will have four oral presentations at EASD, including a symposium hosted by INNODIA focused on life-changing therapies for T1D [2][3] - Key presentations include: - "Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin" by Alexandra Kropotova on September 16, 2025 [2] - "Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes" by Christoph Bausch on September 18, 2025 [3] - "Novel Pharmacokinetic Assay for Measuring SAB-142" and "Specimen Quality for Multicenter Clinical Trials" by Eric Sandhurst on September 18, 2025 [3][4] INNODIA Overview - INNODIA is an international non-profit organization dedicated to preventing and curing type 1 diabetes, stemming from a European public-private partnership [6][7] - It represents a collaboration between those developing new therapies and those with the necessary tools and experience [7]